Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into Late-Stage Testing By Launching Two Global Trials

Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer’s disease.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on June 1st, 2009